3/17/2014 8:51:04 AM
NEW YORK, March 14, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on key development programs.
Help employers find you! Check out all the jobs and post your resume.
comments powered by